22 results on '"Community-Acquired Infections therapy"'
Search Results
2. Hospital Outcomes in Patients Who Developed Acute Respiratory Distress Syndrome After Community-Acquired Pneumonia.
- Author
-
Kasotakis G, Pant P, Patel AD, Ahmed Y, Raghunathan K, Krishnamoorthy V, and Ohnuma T
- Subjects
- Humans, Male, Female, Retrospective Studies, Middle Aged, Aged, Risk Factors, Intensive Care Units statistics & numerical data, Hospitalization statistics & numerical data, Aged, 80 and over, Respiratory Distress Syndrome mortality, Respiratory Distress Syndrome etiology, Respiratory Distress Syndrome therapy, Community-Acquired Infections mortality, Community-Acquired Infections complications, Community-Acquired Infections therapy, Length of Stay statistics & numerical data, Hospital Mortality, Respiration, Artificial statistics & numerical data, Pneumonia mortality, Pneumonia complications, Pneumonia therapy
- Abstract
Purpose: To identify risk factors for and outcomes in acute respiratory distress syndrome (ARDS) in patients hospitalized with community-acquired pneumonia (CAP). Methods: This is a retrospective study using the Premier Healthcare Database between 2016 and 2020. Patients diagnosed with pneumonia, requiring mechanical ventilation (MV), antimicrobial therapy, and hospital admission ≥2 days were included. Multivariable regression models were used for outcomes including in-hospital mortality, hospital length of stay (LOS), intensive care unit (ICU) LOS, and days on MV. Results: 1924 (2.7%) of 72 107 patients with CAP developed ARDS. ARDS was associated with higher mortality (33.7% vs 18.9%; adjusted odds ratio 2.4; 95% confidence interval [CI] 2.16-2.66), longer hospital LOS (13 vs 9 days; adjusted incidence risk ratio (aIRR) 1.24; 95% CI 1.20-1.27), ICU LOS (9 vs 5 days; aIRR 1.51; 95% CI 1.46-1.56), more MV days (8 vs 5; aIRR 1.54; 95% CI 1.48-1.59), and increased hospitalization cost ($46 459 vs $29 441; aIRR 1.50; 95% CI 1.45-1.55). Conclusion: In CAP, ARDS was associated with worse in-patient outcomes in terms of mortality, LOS, and hospitalization cost. Future studies are needed to explore outcomes in patients with CAP with ARDS and explore risk factors for development of ARDS after CAP.
- Published
- 2024
- Full Text
- View/download PDF
3. [New developments in the diagnosis and treatment of community-acquired pneumonia].
- Author
-
Velasquez T, El Maazi S, Bergeron A, Bosetti D, Kaiser L, Gillabert C, Chevallier-Lugon C, and Jalbert B
- Subjects
- Humans, Aged, Practice Guidelines as Topic, SARS-CoV-2, Community-Acquired Infections diagnosis, Community-Acquired Infections therapy, Community-Acquired Infections epidemiology, COVID-19 diagnosis, COVID-19 therapy, COVID-19 epidemiology, Pneumonia diagnosis, Pneumonia therapy, Pneumonia epidemiology
- Abstract
Community acquired pneumonia is a well-known entity in internal medicine. It represents 1.2 cases per 1000 inhabitants every year, and up to 14 cases per 100 inhabitants in people older than 65 years old. Despite our exposition to the disease almost daily, it is still the leading cause of death related to an infection. In 2019, The American Thoracic Society proposed a revision of its guidelines, especially concerning the diagnosis and the treatment of community acquired pneumonia. It is the latest academic society revision. Further-more, the SARS-CoV-2 pandemia has extended our knowledge of pulmonary infection and brought an adaptation of our practice., Competing Interests: Les auteurs n’ont déclaré aucun conflit d’intérêts en relation avec cet article.
- Published
- 2024
- Full Text
- View/download PDF
4. Pitfalls in definitions on respiratory viruses and particularities of Adenovirus infection in hematopoietic cell transplantation patients: Recommendations from the EBMT practice harmonization and guidelines committee.
- Author
-
Piñana JL, Cesaro S, Mikulska M, Verweij PE, Bergeron A, Neofytos D, Styczynski J, Sánchez-Ortega I, Greco R, Onida F, Yakoub-Agha I, Averbuch D, Cámara R, and Ljungman P
- Subjects
- Humans, Adenoviridae Infections therapy, Adenoviridae Infections diagnosis, Adenoviridae Infections epidemiology, Community-Acquired Infections therapy, Community-Acquired Infections epidemiology, Community-Acquired Infections diagnosis, Practice Guidelines as Topic, Consensus, Adenovirus Infections, Human diagnosis, Adenovirus Infections, Human therapy, Adenovirus Infections, Human epidemiology, Adenoviridae isolation & purification, Hematopoietic Stem Cell Transplantation adverse effects, Respiratory Tract Infections therapy, Respiratory Tract Infections diagnosis, Respiratory Tract Infections epidemiology, Respiratory Tract Infections virology
- Abstract
In 2023, the EBMT Practice harmonization and Guidelines Committee partnered with the EBMT Infection Diseases Working Party (IDWP) to undertake the task of delivering best practice recommendations, aiming to harmonize by expert consensus, the already existing definitions and future epidemiological and clinical studies among centers of the EBMT network. To attain this objective, a group of experts in the field was convened. The workgroup identified and discussed some critical aspects in definitions of community-acquired respiratory viruses (CARV) and adenovirus (ADV) infections in recipient of hematopoietic cell transplant (HCT). The methodology involved literature review and expert consensus. For CARV, expert consensus focused on defining infection severity, infection duration, and establishing criteria for lower respiratory tract disease (LRTD). For ADV, the expert consensus focused on surveillance methods and the definitions of ADV infection, certainty levels of disease, response to treatment, and attributable mortality. This consensus workshop provided indications to EBMT community aimed at facilitating data collection and consistency in the EBMT registry for respiratory viral infectious complications., Competing Interests: Declaration of competing interest DA: No conflict of interest to declare. AB: No conflict of interest to declare. SC: No conflict of interest to declare. RdC: Participation in advisory boards for Astra-Zeneca, Astella, Moderna and MSD. Speaker for MSD, Gilead. None of these conflicts were related to this manuscript. RG: speaking honoraria from Biotest, Pfizer, Medac, Neovii and Magenta; none of the mentioned conflicts of interest were related to financing of the content of this manuscript. For non-profit organization, she is a co-chair of the EBMT PH & G committee. PL: Participation in advisory boards for Astra-Zeneca and Moderna. Speaker for MSD. None of these conflicts were related to this manuscript. MM: No conflict of interest to declare. DN: No conflict of interest to declare. FO: Declares no conflict of interest related to this work. For non-profit organization, he is a co-chair of the EBMT PH & G committee. JLP: Declares no conflict of interest related to this work. PV: Participation in advisory boards and speaking honoraria for Gilead Sciences, Pfizer, Mundipharma, F2G and Shionogi. Honoraria were paid to my institute. None of these conflicts were related to this manuscript. ISO: Declares no conflict of interest related to this work. For non-profit organization, she is the current secretary of the EBMT PH & G committee. JS: Declares no conflict of interest related to this work. IYA: Declares no conflict of interest related to this work. For non-profit organization, he is the current chair of the EBMT PH & G committee., (Copyright © 2024. Published by Elsevier Masson SAS.)
- Published
- 2024
- Full Text
- View/download PDF
5. Diagnostic Discordance, Uncertainty, and Treatment Ambiguity in Community-Acquired Pneumonia : A National Cohort Study of 115 U.S. Veterans Affairs Hospitals.
- Author
-
Jones BE, Chapman AB, Ying J, Rutter ED, Nevers MR, Baker A, Dean NC, Fix ML, Singh H, Cosby KS, Taber PA, Weir CD, Jones MM, Samore MH, and Butler JM
- Subjects
- Humans, Retrospective Studies, United States epidemiology, Uncertainty, Male, Female, Middle Aged, Aged, Emergency Service, Hospital statistics & numerical data, Anti-Bacterial Agents therapeutic use, Hospitalization, Diagnostic Errors, Adult, Patient Discharge, Community-Acquired Infections diagnosis, Community-Acquired Infections drug therapy, Community-Acquired Infections therapy, Hospitals, Veterans, Pneumonia diagnosis, Pneumonia drug therapy, Pneumonia therapy
- Abstract
Background: Evidence-based practice in community-acquired pneumonia often assumes an accurate initial diagnosis., Objective: To examine the evolution of pneumonia diagnoses among patients hospitalized from the emergency department (ED)., Design: Retrospective nationwide cohort., Setting: 118 U.S. Veterans Affairs medical centers., Patients: Aged 18 years or older and hospitalized from the ED between 1 January 2015 and 31 January 2022., Measurements: Discordances between initial pneumonia diagnosis, discharge diagnosis, and radiographic diagnosis identified by natural language processing of clinician text, diagnostic coding, and antimicrobial treatment. Expressions of uncertainty in clinical notes, patient illness severity, treatments, and outcomes were compared., Results: Among 2 383 899 hospitalizations, 13.3% received an initial or discharge diagnosis and treatment of pneumonia: 9.1% received an initial diagnosis and 10.0% received a discharge diagnosis. Discordances between initial and discharge occurred in 57%. Among patients discharged with a pneumonia diagnosis and positive initial chest image, 33% lacked an initial diagnosis. Among patients diagnosed initially, 36% lacked a discharge diagnosis and 21% lacked positive initial chest imaging. Uncertainty was frequently expressed in clinical notes (58% in ED; 48% at discharge); 27% received diuretics, 36% received corticosteroids, and 10% received antibiotics, corticosteroids, and diuretics within 24 hours. Patients with discordant diagnoses had greater uncertainty and received more additional treatments, but only patients lacking an initial pneumonia diagnosis had higher 30-day mortality than concordant patients (14.4% [95% CI, 14.1% to 14.7%] vs. 10.6% [CI, 10.4% to 10.7%]). Patients with diagnostic discordance were more likely to present to high-complexity facilities with high ED patient load and inpatient census., Limitation: Retrospective analysis; did not examine causal relationships., Conclusion: More than half of all patients hospitalized and treated for pneumonia had discordant diagnoses from initial presentation to discharge. Treatments for other diagnoses and expressions of uncertainty were common. These findings highlight the need to recognize diagnostic uncertainty and treatment ambiguity in research and practice of pneumonia-related care., Primary Funding Source: The Gordon and Betty Moore Foundation., Competing Interests: Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M23-2505.
- Published
- 2024
- Full Text
- View/download PDF
6. Detection and Management of Elevated Intracranial Pressure in the Treatment of Acute Community-Acquired Bacterial Meningitis: A Systematic Review.
- Author
-
El-Hajj VG, Pettersson I, Gharios M, Ghaith AK, Bydon M, Edström E, and Elmi-Terander A
- Subjects
- Humans, Acute Disease, Intracranial Pressure physiology, Meningitis, Bacterial therapy, Meningitis, Bacterial diagnosis, Meningitis, Bacterial physiopathology, Intracranial Hypertension therapy, Intracranial Hypertension physiopathology, Intracranial Hypertension diagnosis, Community-Acquired Infections therapy
- Abstract
Acute bacterial meningitis (ABM) is associated with severe morbidity and mortality. The most prevalent pathogens in community-acquired ABM are Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae. Other pathogens may affect specific patient groups, such as newborns, older patients, or immunocompromised patients. It is well established that ABM is associated with elevated intracranial pressure (ICP). However, the role of ICP monitoring and management in the treatment of ABM has been poorly described.An electronic search was performed in four electronic databases: PubMed, Web of Science, Embase, and the Cochrane Library. The search strategy chosen for this review used the following terms: Intracranial Pressure AND (management OR monitoring) AND bacterial meningitis. The search yielded a total of 403 studies, of which 18 were selected for inclusion. Eighteen studies were finally included in this review. Only one study was a randomized controlled trial. All studies employed invasive ICP monitoring techniques, whereas some also relied on assessment of ICP-based on clinical and/or radiological observations. The most commonly used invasive tools were external ventricular drains, which were used both to monitor and treat elevated ICP. Results from the included studies revealed a clear association between elevated ICP and mortality, and possibly improved outcomes when invasive ICP monitoring and management were used. Finally, the review highlights the absence of clear standardized protocols for the monitoring and management of ICP in patients with ABM. This review provides an insight into the role of invasive ICP monitoring and ICP-based management in the treatment of ABM. Despite weak evidence certainty, the present literature points toward enhanced patient outcomes in ABM with the use of treatment strategies aiming to normalize ICP using continuous invasive monitoring and cerebrospinal fluid diversion techniques. Continued research is needed to define when and how to employ these strategies to best improve outcomes in ABM., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
7. Parapneumonic empyema in children: a scoping review of the literature.
- Author
-
Buonsenso D, Cusenza F, Passadore L, Bonanno F, Calanca C, Mariani F, Di Martino C, Rasmi S, and Esposito S
- Subjects
- Adolescent, Child, Child, Preschool, Humans, Infant, Anti-Bacterial Agents therapeutic use, Community-Acquired Infections therapy, Drainage, Empyema, Pleural therapy, Empyema, Pleural microbiology
- Abstract
Community-acquired pneumonia can lead to a serious complication called empyema, which refers to pus within the pleural space. While it poses a significant threat to morbidity, particularly in children, it is fortunately not associated with high mortality rates. However, determining the best course of management for children, including decisions regarding antibiotic selection, administration methods, and treatment duration, remains a topic of ongoing debate. This scoping review aims to map the existing literature on empyema in children, including types of studies, microbiology, therapies (both antimicrobial and surgical) and patient outcomes. We systematically searched PubMed and SCOPUS using the terms "pediatric" (encompassing children aged 0 to 18 years) and "pleural empyema" to identify all relevant studies published since 2000. This search adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA ScR) checklist.A total of 127 studies was included. Overall, 15 attempted to compare medical treatments (alone or in combination with pleural drainage or fibrinolysis) with more invasive surgical approaches, and six studies compared diverse surgical interventions. However, the diversity of study designs makes it difficult to derive firm conclusions on the optimal approach to pediatric empyema. The heterogeneity in inclusion criteria, pharmacological/surgical approaches and settings limit the ability to draw definitive conclusions. Overall, 78 out of 10,896 children (0.7%) included in the review died, with mortality being higher in Asia and Africa. Our scoping review highlights important gaps regarding several aspects of empyema in children, including specific serotypes of the most common bacteria involved in the etiology, the optimal pharmacological and surgical approach, and the potential benefits of newer antibiotics with optimal lung penetration. New trials, designed on a multi-country level a higher number of patients and more rigorous inclusion criteria and designs, should be urgently funded., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
8. Effect of Exercise Training on Prognosis in Community-acquired Pneumonia: A Randomized Controlled Trial.
- Author
-
Ryrsø CK, Faurholt-Jepsen D, Ritz C, Hegelund MH, Dungu AM, Pedersen BK, Krogh-Madsen R, and Lindegaard B
- Subjects
- Humans, Male, Female, Aged, Middle Aged, Prognosis, Length of Stay statistics & numerical data, Patient Readmission statistics & numerical data, Exercise Therapy methods, Treatment Outcome, Aged, 80 and over, Exercise physiology, Community-Acquired Infections mortality, Community-Acquired Infections therapy, Pneumonia mortality, Pneumonia therapy
- Abstract
Objective: To investigate the effect of standard care (SoC) combined with supervised in-bed cycling (Bed-Cycle) or booklet exercises (Book-Exe) versus SoC in community-acquired pneumonia (CAP)., Methods: In this randomized controlled trial, 186 patients with CAP were assigned to SoC (n = 62), Bed-Cycle (n = 61), or Book-Exe (n = 63). Primary outcome length of stay (LOS) was analyzed with analysis of covariance. Secondary outcomes, 90-day readmission, and 180-day mortality were analyzed with Cox proportional hazard regression and readmission days with negative-binominal regression., Results: LOS was -2% (95% CI: -24 to 25) and -1% (95% CI: -22 to 27) for Bed-Cycle and Book-Exe, compared with SoC. Ninety-day readmission was 35.6% for SoC, 27.6% for Bed-Cycle, and 21.3% for Book-Exe. Adjusted hazard ratio (aHR) for 90-day readmission was 0.63 (95% CI: .33-1.21) and 0.54 (95% CI: .27-1.08) for Bed-Cycle and Book-Exe compared with SoC. aHR for 90-day readmission for combined exercise was 0.59 (95% CI: .33-1.03) compared with SoC. aHR for 180-day mortality was 0.84 (95% CI: .27-2.60) and 0.82 (95% CI: .26-2.55) for Bed-Cycle and Book-Exe compared with SoC. Number of readmission days was 226 for SoC, 161 for Bed-Cycle, and 179 for Book-Exe. Incidence rate ratio for readmission days was 0.73 (95% CI: .48-1.10) and 0.77 (95% CI: .51-1.15) for Bed-Cycle and Book-Exe compared with SoC., Conclusions: Although supervised exercise training during admission with CAP did not reduce LOS or mortality, this trial suggests its potential to reduce readmission risk and number of readmission days., Clinical Trials Registration: NCT04094636., Competing Interests: Potential conflicts of interest. The authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest., (© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America.)
- Published
- 2024
- Full Text
- View/download PDF
9. Prospective, randomized, controlled trial assessing the effects of a driving pressure-limiting strategy for patients with acute respiratory distress syndrome due to community-acquired pneumonia (STAMINA trial): protocol and statistical analysis plan.
- Author
-
Maia IS, Medrado FA Jr, Tramujas L, Tomazini BM, Oliveira JS, Sady ERR, Barbante LG, Nicola ML, Gurgel RM, Damiani LP, Negrelli KL, Miranda TA, Santucci E, Valeis N, Laranjeira LN, Westphal GA, Fernandes RP, Zandonai CL, Pincelli MP, Figueiredo RC, Bustamante CLS, Norbin LF, Boschi E, Lessa R, Romano MP, Miura MC, Alencar Filho MS, Dantas VCS, Barreto PA, Hernandes ME, Grion CMC, Laranjeira AS, Mezzaroba AL, Bahl M, Starke AC, Biondi RS, Dal-Pizzol F, Caser EB, Thompson MM, Padial AA, Veiga VC, Leite RT, Araújo G, Guimarães M, Martins PA, Lacerda FH, Hoffmann Filho CR, Melro L, Pacheco E, Ospina-Táscon GA, Ferreira JC, Freires FJC, Machado FR, Cavalcanti AB, and Zampieri FG
- Subjects
- Humans, Brazil epidemiology, Colombia epidemiology, Intensive Care Units, Pneumonia therapy, Prospective Studies, Tidal Volume, Randomized Controlled Trials as Topic, Multicenter Studies as Topic, Community-Acquired Infections therapy, Positive-Pressure Respiration methods, Respiratory Distress Syndrome therapy, Respiratory Distress Syndrome physiopathology
- Abstract
Background: Driving pressure has been suggested to be the main driver of ventilator-induced lung injury and mortality in observational studies of acute respiratory distress syndrome. Whether a driving pressure-limiting strategy can improve clinical outcomes is unclear., Objective: To describe the protocol and statistical analysis plan that will be used to test whether a driving pressure-limiting strategy including positive end-expiratory pressure titration according to the best respiratory compliance and reduction in tidal volume is superior to a standard strategy involving the use of the ARDSNet low-positive end-expiratory pressure table in terms of increasing the number of ventilator-free days in patients with acute respiratory distress syndrome due to community-acquired pneumonia., Methods: The ventilator STrAtegy for coMmunIty acquired pNeumoniA (STAMINA) study is a randomized, multicenter, open-label trial that compares a driving pressure-limiting strategy to the ARDSnet low-positive end-expiratory pressure table in patients with moderate-to-severe acute respiratory distress syndrome due to community-acquired pneumonia admitted to intensive care units. We expect to recruit 500 patients from 20 Brazilian and 2 Colombian intensive care units. They will be randomized to a driving pressure-limiting strategy group or to a standard strategy using the ARDSNet low-positive end-expiratory pressure table. In the driving pressure-limiting strategy group, positive end-expiratory pressure will be titrated according to the best respiratory system compliance., Outcomes: The primary outcome is the number of ventilator-free days within 28 days. The secondary outcomes are in-hospital and intensive care unit mortality and the need for rescue therapies such as extracorporeal life support, recruitment maneuvers and inhaled nitric oxide., Conclusion: STAMINA is designed to provide evidence on whether a driving pressure-limiting strategy is superior to the ARDSNet low-positive end-expiratory pressure table strategy for increasing the number of ventilator-free days within 28 days in patients with moderate-to-severe acute respiratory distress syndrome. Here, we describe the rationale, design and status of the trial.
- Published
- 2024
- Full Text
- View/download PDF
10. Study: Roughly 1 in 8 Patients Wrongly Diagnosed With Pneumonia.
- Author
-
Harris E
- Subjects
- Humans, Anti-Bacterial Agents administration & dosage, Anti-Bacterial Agents adverse effects, Inappropriate Prescribing, Community-Acquired Infections diagnosis, Community-Acquired Infections diagnostic imaging, Community-Acquired Infections drug therapy, Community-Acquired Infections therapy, Michigan epidemiology, Hospitalization statistics & numerical data, Diagnostic Errors adverse effects, Diagnostic Errors statistics & numerical data, Pneumonia diagnosis, Pneumonia drug therapy, Pneumonia epidemiology, Health Services Misuse statistics & numerical data
- Published
- 2024
- Full Text
- View/download PDF
11. The Meat of the Matter.
- Author
-
Rutenberg D, Zhang Y, Montoya JG, Sinnott J, and Contopoulos-Ioannidis DG
- Subjects
- Female, Humans, Bronchoscopy, Cell-Free Nucleic Acids blood, Community-Acquired Infections blood, Community-Acquired Infections diagnosis, Community-Acquired Infections etiology, Community-Acquired Infections therapy, DNA, Protozoan blood, DNA, Protozoan isolation & purification, Hypoxia blood, Hypoxia diagnosis, Hypoxia etiology, Hypoxia therapy, Immunocompetence, Medical History Taking, Respiratory Insufficiency blood, Respiratory Insufficiency diagnosis, Respiratory Insufficiency therapy, Treatment Outcome, Deer parasitology, Pneumonia blood, Pneumonia diagnosis, Pneumonia etiology, Pneumonia therapy, Toxoplasma isolation & purification, Toxoplasmosis blood, Toxoplasmosis diagnosis, Toxoplasmosis etiology, Toxoplasmosis therapy, Zoonoses blood, Zoonoses diagnosis, Zoonoses etiology, Zoonoses therapy
- Published
- 2024
- Full Text
- View/download PDF
12. Socio-demographic and comorbid risk factors for poor prognosis in patients hospitalized with community-acquired bacterial pneumonia in southeastern US.
- Author
-
Idigo AJ, Wells JM, Brown ML, Wiener HW, Griffin RL, Cutter G, Shrestha S, and Lee RA
- Subjects
- Male, Adult, Humans, Aged, Hospitalization, Length of Stay, Prognosis, Risk Factors, Obesity, Hospital Mortality, Retrospective Studies, Diabetes Mellitus, Type 2, Pneumonia epidemiology, Pneumonia therapy, Community-Acquired Infections epidemiology, Community-Acquired Infections therapy, Stroke, Heart Failure epidemiology, Pneumonia, Bacterial
- Abstract
Background: How socio-demographic characteristics and comorbidities affect bacterial community-acquired pneumonia (CAP) prognosis during/after hospitalization is important in disease management., Objectives: To identify predictors of medical intensive care unit (MICU) admission, length of hospital stay (LOS), in-hospital mortality, and bacterial CAP readmission in patients hospitalized with bacterial CAP., Methods: ICD-9/10 codes were used to query electronic medical records to identify a cohort of patients hospitalized for bacterial CAP at a tertiary hospital in Southeastern US between 01/01/2013-12/31/2019. Adjusted accelerated failure time and modified Poisson regression models were used to examine predictors of MICU admission, LOS, in-hospital mortality, and 1-year readmission., Results: There were 1956 adults hospitalized with bacterial CAP. Median (interquartile range) LOS was 11 days (6-23), and there were 26 % (513) MICU admission, 14 % (266) in-hospital mortality, and 6 % (117) 1-year readmission with recurrent CAP. MICU admission was associated with heart failure (RR 1.38; 95 % CI 1.17-1.62) and obesity (RR 1.26; 95 % CI 1.04-1.52). Longer LOS was associated with heart failure (adjusted time ratio[TR] 1.27;95 %CI 1.12-1.43), stroke (TR 1.90;95 %CI 1.54,2.35), type 2 diabetes (TR 1.20;95 %CI 1.07-1.36), obesity (TR 1.50;95 %CI 1.31-1.72), Black race (TR 1.17;95 %CI 1.04-1.31), and males (TR 1.24;95 %CI 1.10-1.39). In-hospital mortality was associated with stroke (RR 1.45;95 %CI 1.03-2.04) and age ≥65 years (RR 1.34;95 %CI 1.06-1.68). 1-year readmission was associated with COPD (RR 1.55;95 %CI 1.05-2.27) and underweight BMI (RR 1.74;95 %CI 1.04-2.90)., Conclusions: Comorbidities and socio-demographic characteristics have varying impacts on bacterial CAP in-hospital prognosis and readmission. More studies are warranted to confirm these findings to develop comprehensive care plans and inform public health interventions., Competing Interests: Declaration of competing interest No conflicts exist for AJI, MLB, HWW, RLG, SS, and RAL., (Published by Elsevier Inc.)
- Published
- 2024
- Full Text
- View/download PDF
13. Artificial intelligence for the optimal management of community-acquired pneumonia.
- Author
-
Barbieri MA, Battini V, and Sessa M
- Subjects
- Humans, Artificial Intelligence, Algorithms, Hospitalization, Community-Acquired Infections diagnosis, Community-Acquired Infections therapy, Pneumonia diagnosis, Pneumonia therapy
- Abstract
Purpose of Review: This timely review explores the integration of artificial intelligence (AI) into community-acquired pneumonia (CAP) management, emphasizing its relevance in predicting the risk of hospitalization. With CAP remaining a global public health concern, the review highlights the need for efficient and reliable AI tools to optimize resource allocation and improve patient outcomes., Recent Findings: Challenges in CAP management delve into the application of AI in predicting CAP-related hospitalization risks, and complications, and mortality. The integration of AI-based risk scores in managing CAP has the potential to enhance the accuracy of predicting patients at higher risk, facilitating timely intervention and resource allocation. Moreover, AI algorithms reduce variability associated with subjective clinical judgment, promoting consistency in decision-making, and provide real-time risk assessments, aiding in the dynamic management of patients with CAP., Summary: The development and implementation of AI-tools for hospitalization in CAP represent a transformative approach to improving patient outcomes. The integration of AI into healthcare has the potential to revolutionize the way we identify and manage individuals at risk of severe outcomes, ultimately leading to more efficient resource utilization and better overall patient care., (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
14. Optimizing Diagnosis and Management of Community-acquired Pneumonia in the Emergency Department.
- Author
-
Hunold KM, Rozycki E, and Brummel N
- Subjects
- Humans, Emergency Service, Hospital, Anti-Bacterial Agents therapeutic use, Pneumonia therapy, Pneumonia drug therapy, Pneumonia, Ventilator-Associated, Community-Acquired Infections therapy, Community-Acquired Infections drug therapy
- Abstract
Pneumonia is split into 3 diagnostic categories: community-acquired pneumonia (CAP), health care-associated pneumonia, and ventilator-associated pneumonia. This classification scheme is driven not only by the location of infection onset but also by the predominant associated causal microorganisms. Pneumonia is diagnosed in over 1.5 million US emergency department visits annually (1.2% of all visits), and most pneumonia diagnosed by emergency physicians is CAP., Competing Interests: Disclosure Dr K.M. Hunold is funded by the NIH under award K76AG074941 and R01AG071018. Dr N. Brummel is supported by the NIH under awards R01HD107103 and R01AG077644., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
15. Comparison of outcomes and characteristics of patients admitted to the ICU with COVID-19 and other community-acquired pneumonia based on propensity score matching.
- Author
-
Zhao H, Yan X, Guo Z, Li K, Wang Z, Wang J, Lv D, Zhu J, and Chen Y
- Subjects
- Humans, Male, Female, Middle Aged, Aged, Hospitalization statistics & numerical data, China epidemiology, Retrospective Studies, Antiviral Agents therapeutic use, Length of Stay statistics & numerical data, Adult, Treatment Outcome, Prognosis, Pneumonia mortality, Pneumonia therapy, COVID-19 mortality, COVID-19 therapy, COVID-19 epidemiology, Propensity Score, Community-Acquired Infections mortality, Community-Acquired Infections therapy, Community-Acquired Infections epidemiology, Intensive Care Units statistics & numerical data, SARS-CoV-2
- Abstract
Objective: To compare the similarities and differences between patients with Coronavirus Disease 2019 (COVID-19) and those with other community-acquired pneumonia (CAP) admitted to the intensive care unit (ICU), utilizing propensity score matching (PSM), regarding hospitalization expenses, treatment options, and prognostic outcomes, aiming to inform the diagnosis and treatment of COVID-19., Methods: Patients admitted to the ICU of the Third People's Hospital of Datong City, diagnosed with COVID-19 from December 2022 to February 2023, constituted the observation group, while those with other CAP admitted from January to November 2022 formed the control group. Basic information, clinical data at admission, and time from symptom onset to admission were matched using PSM., Results: A total of 70 patients were included in the COVID-19 group and 119 in the CAP group. The patients were matched by the propensity matching method, and 37 patients were included in each of the last two groups. After matching, COVID-19 had a higher failure rate than CAP, but the difference was not statistically significant (73% vs. 51%, p = 0.055). The utilization rate of antiviral drugs (40% vs. 11%, p = 0.003), γ-globulin (19% vs. 0%, p = 0.011) and prone position ventilation (PPV) (27% vs. 0%, p < 0.001) in patients with COVID-19 were higher than those in the CAP, and the differences were statistically significant. The total hospitalization cost of COVID-19 patients was lower than that of CAP patients, and the difference was statistically significant (27889.5 vs. 50175.9, p = 0.007). The hospital stay for COVID-19 patients was shorter than for CAP patients, but the difference was not statistically significant (10.9 vs. 16.6, p = 0.071)., Conclusion: Our findings suggest that limited medical resources influenced patient outcomes during the COVID-19 pandemic. Addressing substantial demands for ICU capacity and medications during this period could have potentially reduced the mortality rate among COVID-19 patients., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
16. Severe Community-Acquired Pneumonia.
- Author
-
Martin-Loeches I and Torres A
- Subjects
- Humans, Pneumonia therapy, Community-Acquired Infections epidemiology, Community-Acquired Infections therapy
- Abstract
Competing Interests: Disclosure The authors report no conflicts of interest in this work.
- Published
- 2024
- Full Text
- View/download PDF
17. Severe Community-Acquired Pneumonia in Immunocompromised Patients.
- Author
-
Chean D, Windsor C, Lafarge A, Dupont T, Nakaa S, Whiting L, Joseph A, Lemiale V, and Azoulay E
- Subjects
- Humans, Quality of Life, Respiration, Artificial, Immunocompromised Host, Intensive Care Units, Noninvasive Ventilation, Pneumonia, Pneumonia, Bacterial, Community-Acquired Infections therapy
- Abstract
Due to higher survival rates with good quality of life, related to new treatments in the fields of oncology, hematology, and transplantation, the number of immunocompromised patients is increasing. But these patients are at high risk of intensive care unit admission because of numerous complications. Acute respiratory failure due to severe community-acquired pneumonia is one of the leading causes of admission. In this setting, the need for invasive mechanical ventilation is up to 60%, associated with a high hospital mortality rate of around 40 to 50%. A wide range of pathogens according to the reason of immunosuppression is associated with severe pneumonia in those patients: documented bacterial pneumonia represents a third of cases, viral and fungal pneumonia both account for up to 15% of cases. For patients with an undetermined etiology despite comprehensive diagnostic workup, the hospital mortality rate is very high. Thus, a standardized diagnosis strategy should be defined to increase the diagnosis rate and prescribe the appropriate treatment. This review focuses on the benefit-to-risk ratio of invasive or noninvasive strategies, in the era of omics, for the management of critically ill immunocompromised patients with severe pneumonia in terms of diagnosis and oxygenation., Competing Interests: Disclosure The authors report no conflicts of interest in this work., (Thieme. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
18. Severe Community-Acquired Pneumonia: Noninvasive Mechanical Ventilation, Intubation, and HFNT.
- Author
-
Ferrer M, De Pascale G, Tanzarella ES, and Antonelli M
- Subjects
- Humans, Respiration, Artificial, Intubation, Intratracheal, Oxygen, Noninvasive Ventilation methods, Pneumonia, Respiratory Insufficiency therapy, Respiratory Distress Syndrome therapy, Community-Acquired Infections therapy
- Abstract
Severe acute respiratory failure (ARF) is a major issue in patients with severe community-acquired pneumonia (CAP). Standard oxygen therapy is the first-line therapy for ARF in the less severe cases. However, respiratory supports may be delivered in more severe clinical condition. In cases with life-threatening ARF, invasive mechanical ventilation (IMV) will be required. Noninvasive strategies such as high-flow nasal therapy (HFNT) or noninvasive ventilation (NIV) by either face mask or helmet might cover the gap between standard oxygen and IMV. The objective of all the supporting measures for ARF is to gain time for the antimicrobial treatment to cure the pneumonia. There is uncertainty regarding which patients with severe CAP are most likely to benefit from each noninvasive support strategy. HFNT may be the first-line approach in the majority of patients. While NIV may be relatively contraindicated in patients with excessive secretions, facial hair/structure resulting in air leaks or poor compliance, NIV may be preferable in those with increased work of breathing, respiratory muscle fatigue, and congestive heart failure, in which the positive pressure of NIV may positively impact hemodynamics. A trial of NIV might be considered for select patients with hypoxemic ARF if there are no contraindications, with close monitoring by an experienced clinical team who can intubate patients promptly if they deteriorate. In such cases, individual clinician judgement is key to choose NIV, interface, and settings. Due to the paucity of studies addressing IMV in this population, the protective mechanical ventilation strategies recommended by guidelines for acute respiratory distress syndrome can be reasonably applied in patients with severe CAP., Competing Interests: None declared., (Thieme. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
19. Biomarkers: Are They Useful in Severe Community-Acquired Pneumonia?
- Author
-
Póvoa P, Pitrowsky M, Guerreiro G, Pacheco MB, and Salluh JIF
- Subjects
- Humans, Prospective Studies, Biomarkers, Sensitivity and Specificity, Prognosis, Pneumonia diagnosis, Pneumonia, Viral diagnosis, Community-Acquired Infections diagnosis, Community-Acquired Infections therapy
- Abstract
Community acquired pneumonia (CAP) is a prevalent infectious disease often requiring hospitalization, although its diagnosis remains challenging as there is no gold standard test. In severe CAP, clinical and radiologic criteria have poor sensitivity and specificity, and microbiologic documentation is usually delayed and obtained in less than half of sCAP patients. Biomarkers could be an alternative for diagnosis, treatment monitoring and establish resolution. Beyond the existing evidence about biomarkers as an adjunct diagnostic tool, most evidence comes from studies including CAP patients in primary care or emergency departments, and not only sCAP patients. Ideally, biomarkers used in combination with signs, symptoms, and radiological findings can improve clinical judgment to confirm or rule out CAP diagnosis, and may be valuable adjunctive tools for risk stratification, differentiate viral pneumonia and monitoring the course of CAP. While no single biomarker has emerged as an ideal one, CRP and PCT have gathered the most evidence. Overall, biomarkers offer valuable information and can enhance clinical decision-making in the management of CAP, but further research and validation are needed to establish their optimal use and clinical utility., Competing Interests: None declared., (Thieme. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
20. Challenges for a broad international implementation of the current severe community-acquired pneumonia guidelines.
- Author
-
Salluh JIF, Póvoa P, Beane A, Kalil A, Sendagire C, Sweeney DA, Pilcher D, Polverino E, Tacconelli E, Estenssoro E, Frat JP, Ramirez J, Reyes LF, Roca O, Nseir S, Nobre V, Lisboa T, and Martin-Loeches I
- Subjects
- Humans, Intensive Care Units, Hospitalization, Pneumonia therapy, Pneumonia drug therapy, Community-Acquired Infections therapy, Community-Acquired Infections drug therapy
- Abstract
Severe community-acquired pneumonia (sCAP) remains one of the leading causes of admission to the intensive care unit, thus consuming a large share of resources and is associated with high mortality rates worldwide. The evidence generated by clinical studies in the last decade was translated into recommendations according to the first published guidelines focusing on severe community-acquired pneumonia. Despite the advances proposed by the present guidelines, several challenges preclude the prompt implementation of these diagnostic and therapeutic measures. The present article discusses the challenges for the broad implementation of the sCAP guidelines and proposes solutions when applicable., (© 2024. Springer-Verlag GmbH Germany, part of Springer Nature.)
- Published
- 2024
- Full Text
- View/download PDF
21. Childhood community-acquired pneumonia.
- Author
-
Meyer Sauteur PM
- Subjects
- Child, Humans, Streptococcus pneumoniae, Bacteria, Anti-Bacterial Agents therapeutic use, Pneumonia, Bacterial diagnosis, Pneumonia, Bacterial drug therapy, Pneumonia, Bacterial epidemiology, Pneumonia diagnosis, Pneumonia epidemiology, Pneumonia etiology, Vaccines, Community-Acquired Infections diagnosis, Community-Acquired Infections epidemiology, Community-Acquired Infections therapy
- Abstract
Community-acquired pneumonia (CAP) is a common disease in children, and its aetiological and clinical diagnosis are challenging for physicians in both private practice and hospitals. Over the past three decades, conjugate vaccines have successfully reduced the burden of the former main causes of CAP, Streptococcus pneumoniae and Haemophilus influenzae type b. Today, viruses are by far the most commonly detected pathogens in children with CAP. Conclusion: New insights into the aetiology and treatment of CAP in children in recent years have influenced management and are the focus of this review. In addition to reducing diagnostic uncertainty, there is an urgent need to reduce antibiotic overuse and antimicrobial resistance in children with CAP. What is Known: • Conjugate vaccines against Streptococcus pneumoniae and Haemophilus influenzae type b have shifted the epidemiology of childhood CAP to predominantly viral pathogens and Mycoplasma pneumoniae. • Clinical, laboratory, and radiological criteria cannot reliably distinguish between bacterial and viral aetiology in children with CAP. What is New: • Test results and epidemiological data must be carefully interpreted, as no single diagnostic method applied to non-pulmonary specimens has both high sensitivity and high specificity for determining pneumonia aetiology in childhood CAP. • This review provides a simple and pragmatic management algorithm for children with CAP to aid physicians in providing optimal and safe care and reducing antibiotic prescribing., (© 2023. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
22. The prevalence of acute kidney injury in patients with community-acquired pneumonia who required mechanical ventilation.
- Author
-
Almutairi A, Alenezi F, Tamim H, Sadat M, Humaid FB, AlMatrood A, Syed Y, and Arabi Y
- Subjects
- Humans, Female, Prevalence, Respiration, Artificial, Retrospective Studies, Acute Kidney Injury epidemiology, Acute Kidney Injury etiology, Acute Kidney Injury therapy, Pneumonia epidemiology, Community-Acquired Infections epidemiology, Community-Acquired Infections therapy
- Abstract
Background: Community-acquired pneumonia (CAP) is a common reason for intensive care unit (ICU) admission and sepsis. Acute kidney injury (AKI) is a frequent complication of community-acquired pneumonia and is associated with increased short- and long-term morbidity and mortality and healthcare costs., Objective: Describe the prevalence of AKI in patients with CAP requiring mechanical ventilation and evaluate its association with inhospital mortality., Design: Retrospective cohort., Setting: Intensive care unit., Patients and Methods: We included patients with CAP on mechanical ventilation. Patients were categorized according to the development of AKI in the first 24 hours of ICU admission using the Kidney Disease Improving Global Outcomes (KDIGO) classification from no AKI, stage 1 AKI, stage 2 AKI, and stage 3 AKI., Main Outcome Measures: The primary outcome was hospital mortality. Secondary outcomes were ICU mortality, hospital and ICU length of stay, ventilation duration, tracheostomy, and renal replacement therapy requirement., Results: Of 1536 patients included in the study, 829 patients (54%) had no AKI while 707 (46%) developed AKI. In-hospital mortality was 288/829 (34.8%) for patients with no AKI, 43/111 (38.7%) for stage 1 AKI, 86/216 (40%) for stage 2 AKI, and 196/380 (51.7%) for stage 3 AKI ( P <.0001). Multivariate analysis revealed that stages 1, 2, or 3 AKI compared to no AKI were not independently associated with in-hospital mortality. Older age, vasopressor use; decreased Glasgow coma scale, PaO
2 /Fio2 ratio and platelet count, increased bilirubin, lactic acid and INR were associated with increased mortality while female sex was associated with reduced mortality., Conclusion: Among mechanically ventilated patients with CAP, AKI was common and was associated with higher crude mortality. The higher mortality could not be attributed alone to AKI, but rather appeared to be related to multi-organ dysfunction., Limitations: Single-center retrospective study with no data on baseline serum creatinine and the use of estimated baseline creatinine distributions based on the MDRD (Modification of Diet in Renal Disease)equation which may lead to an overestimation of AKI. Second, we did not have data on the microbiology of pneumonia, appropriateness of antibiotic therapy or the administration of other medications that have been demonstrated to be associated with AKI., Competing Interests: CONFLICT OF INTEREST: None.- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.